Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.
Administration, Intravenous
Aged
Anti-Inflammatory Agents
/ administration & dosage
Ascorbic Acid
/ administration & dosage
Drug Therapy, Combination
Female
Hospital Mortality
Humans
Hydrocortisone
/ administration & dosage
Male
Middle Aged
Shock, Septic
/ drug therapy
Thiamine
/ therapeutic use
Vasoconstrictor Agents
/ therapeutic use
Vitamins
/ administration & dosage
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
pubmed:
18
1
2020
medline:
7
10
2020
entrez:
18
1
2020
Statut:
ppublish
Résumé
It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock. To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock. Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019. Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days. The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality. Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was -0.6 hours (95% CI, -8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported. In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone. ClinicalTrials.gov Identifier: NCT03333278.
Identifiants
pubmed: 31950979
pii: 2759414
doi: 10.1001/jama.2019.22176
pmc: PMC7029761
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Vasoconstrictor Agents
0
Vitamins
0
Ascorbic Acid
PQ6CK8PD0R
Hydrocortisone
WI4X0X7BPJ
Thiamine
X66NSO3N35
Banques de données
ClinicalTrials.gov
['NCT03333278']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-431Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Crit Care Resusc. 2019 Dec;21(4):236-42
pubmed: 31778629
N Engl J Med. 2018 Mar 01;378(9):797-808
pubmed: 29347874
J Crit Care. 2010 Dec;25(4):576-81
pubmed: 20646908
Crit Care Resusc. 2019 Sep;21(3):152-155
pubmed: 31462200
J Nutr Sci Vitaminol (Tokyo). 2018;64(6):404-411
pubmed: 30606963
Int J Nephrol. 2011;2011:146927
pubmed: 21603151
Chest. 2017 Jun;151(6):1229-1238
pubmed: 27940189
JAMA. 1995 Feb 1;273(5):408-12
pubmed: 7823387
Crit Care Med. 2018 Nov;46(11):1747-1752
pubmed: 30028362
BMJ Open. 2019 Nov 12;9(11):e033458
pubmed: 31722954
Crit Care Resusc. 2019 Jun;21(2):119-125
pubmed: 31142242
N Engl J Med. 2018 Mar 01;378(9):809-818
pubmed: 29490185
FASEB J. 2003 Oct;17(13):1928-30
pubmed: 12897061
JAMA. 2019 Oct 1;322(13):1257-1258
pubmed: 31573621
Am J Kidney Dis. 2013 Jun;61(6):1032-5
pubmed: 23548555
Crit Care Med. 2016 Feb;44(2):360-7
pubmed: 26771781
Antioxidants (Basel). 2017 Jun 29;6(3):
pubmed: 28661424
Am J Physiol Lung Cell Mol Physiol. 2012 Jul 1;303(1):L20-32
pubmed: 22523283
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
N Engl J Med. 2017 Aug 3;377(5):419-430
pubmed: 28528561
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
JAMA. 2019 Oct 1;322(13):1261-1270
pubmed: 31573637
J Biomed Inform. 2013 Apr;46(2):259-65
pubmed: 23149159
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
JAMA. 2014 Jul 2;312(1):90-2
pubmed: 24838355
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
J Transl Med. 2014 Jan 31;12:32
pubmed: 24484547